Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Enzalutamide Pricing Debate Goes to Washington

May 1st 2016

Enzalutamide (Xtandi) pricing heightens the likelihood of pre-authorization requirements and cost-sharing arrangements that may be financially burdensome, ruinous, or simply impossible to meet.

Preventing and Treating Bone Metastases in mCRPC

April 30th 2016

Bone metastases in metastatic castration-resistant prostate cancer can invade a range of sites in the skeleton where they precipitate a spectrum of pathological processes that increase morbidity, negatively affect quality of life, and decrease survival.

Radium-223 May Enhance Immune Response With Sipuleucel-T in mCRPC

April 26th 2016

Jong Chul Park, MD, discusses the potential synergy of radium-223 and sipuleucel-T, which is being investigated in a clinical trial as a potential treatment for patients with metastatic castration-resistant prostate cancer.

The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations

April 25th 2016

Researchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.

Analysis of Real-World Data for Next-Generation Antiandrogen Therapies

April 25th 2016

Real-world data obtained from large retrospective studies can also deliver useful insights into the clinical challenges associated with newer therapies in prostate cancer, such as medication adherence and cognitive adverse events.

Dr. Stock on the Optimal Use of Radium-223 in mCRPC

April 25th 2016

Richard G. Stock, MD, senior faculty, Radiation Oncology, Mount Sinai Hospital, discusses the optimal use of radium-223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer.

Optimal Sequencing Explored for Enzalutamide and Abiraterone in mCRPC

April 22nd 2016

Although abiraterone acetate (Zytiga) and enzalutamide (Xtandi) have demonstrated improved survival outcomes, the optimal sequencing of these therapies has not been established, and most patients exhibit some degree of cross-resistance.

Radium-223 Combinations on Horizon in mCRPC

April 21st 2016

Oliver Sartor, MD, discusses the combination regimens being explored with radium-223, its unique mechanism of action, and the associated risks and benefits.

Experts Discuss Treatment Sequencing Strategies in CRPC

April 19th 2016

E. David Crawford, MD, and Leonard G. Gomella, MD, provide insight into current best practices and strategies that are on the horizon in metastatic castration-resistant prostate cancer.

Addressing Therapeutic Challenges for Geriatric Patients With mCRPC

April 15th 2016

Clinicians must consider and evaluate the unique characteristics and treatment options for older men with prostate cancer, who are more likely to be diagnosed with advanced disease, and tend to have higher mortality rates and poorer prognosis.

Dr. Mohler on Overuse of ADT in Prostate Cancer and NCCN Guidelines

April 1st 2016

James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses the use of androgen-deprivation therapy (ADT) for patients with prostate cancer and how the use is reflected in the NCCN guidelines.

Dr. Gomella on Current Perspectives on Prostate Cancer Screening

April 1st 2016

Leonard Gomella, MD, physician, professor, and chair of the Department of Urology at Thomas Jefferson University and director of the Kimmel Cancer Center Network, discusses the current perspectives on screening for prostate cancer.

Gomella Discusses Radium-223 Impact in mCRPC

March 23rd 2016

Leonard Gomella, MD, discusses the optimal patient population to receive radium-223 for prostate cancer and how oncologists should best use it.

Questions Loom Over Androgen-Targeting Strategies in Metastatic Prostate Cancer

March 22nd 2016

Targeting androgen receptor signaling with recently approved agents has improved outcomes for men with metastatic castration-resistant prostate cancer but significant questions linger about how to tackle resistance to the therapies.

Expert Says Radium-223 Emerged as “Surprise” Solution to Improving OS in mCRPC

March 22nd 2016

E. David Crawford, MD, discusses the history of radium-223 dichloride (Xofigo) and how it could be used in the future.

Dr. Dreicer on the Optimal Use of Radium-223 in Prostate Cancer

March 21st 2016

Robert Dreicer, MD, professor, Department of Medicine, Division of Hematology/Oncology, University of Virginia Health System, discusses the optimal use of radium-223 dichloride (Xofigo) for patients with metastatic castration-resistant prostate cancer.

Beyond PSA: What's Next for Prostate Cancer Detection?

March 17th 2016

Stacy Loeb, MD, discusses how screening tests for prostate cancer work, what their benefits are, and what urological specialists need to know in order to best utilize them.

Earlier Abiraterone More Effective for Chemo-NaÃ¯ve mCRPC

March 14th 2016

Treatment with abiraterone acetate plus prednisone demonstrated an 11.8-month improvement in overall survival compared with prednisone and placebo for men with less advanced, chemotherapy-naÃ¯ve metastatic castration-resistant prostate cancer.

Quality of Life Scores Similar in Men Undergoing Active Surveillance Versus Those Without Prostate Cancer

March 14th 2016

Men with low-risk prostate cancer who chose active surveillance (AS) reported a higher quality of life than men who chose direct active treatment such as surgery or radiation.

Secondary Cancers Linked to Radiotherapy in Men With Prostate Cancer

March 9th 2016

Men with prostate cancer treated with radiotherapy were at higher risk for developing second malignancies in the bladder, colon, and rectum compared with men who were not exposed to radiotherapy.